PureTech Health plc (NASDAQ:PRTC - Free Report) - Equities researchers at Leerink Partnrs increased their FY2025 EPS estimates for PureTech Health in a note issued to investors on Wednesday, April 30th. Leerink Partnrs analyst F. Khurshid now expects that the company will post earnings of ($4.28) per share for the year, up from their prior forecast of ($4.84). The consensus estimate for PureTech Health's current full-year earnings is ($4.34) per share. Leerink Partnrs also issued estimates for PureTech Health's FY2026 earnings at ($4.37) EPS.
PureTech Health Stock Down 1.3 %
PureTech Health stock traded down $0.22 during trading on Monday, reaching $17.03. 1,138 shares of the company's stock were exchanged, compared to its average volume of 4,752. PureTech Health has a 52-week low of $13.30 and a 52-week high of $32.98. The company's 50-day moving average is $17.32 and its two-hundred day moving average is $19.01.
Institutional Investors Weigh In On PureTech Health
An institutional investor recently bought a new position in PureTech Health stock. Millennium Management LLC purchased a new stake in PureTech Health plc (NASDAQ:PRTC - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 45,264 shares of the company's stock, valued at approximately $823,000. Millennium Management LLC owned about 0.19% of PureTech Health as of its most recent filing with the Securities and Exchange Commission (SEC). 0.04% of the stock is currently owned by institutional investors.
About PureTech Health
(
Get Free Report)
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.
Read More
Before you consider PureTech Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.
While PureTech Health currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
